Insider transaction
Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported that Chief Medical Officer Helen Louise Collins sold 5,000 shares of the company's common stock on March 17, 2026. The shares were sold at prices between $27.40 and $28.2278, producing proceeds of $138,800.
Concurrent option exercise
On the same date Collins exercised stock options to purchase 5,000 shares at an exercise price of $2.48 per share, for a total cash outlay of $12,400 to acquire those option shares.
Ownership and trading plan
The sales and the option exercise were carried out under a pre-arranged trading plan that Collins adopted on October 19, 2025. After completing the sale, Collins directly holds 25,000 shares of Enliven Therapeutics.
Share-price context
At the time of reporting, Enliven shares have climbed to $30.05, trading close to their 52-week high of $31.75. The stock has risen 58% over the past six months.
Valuation note
Analysis from InvestingPro included in the company commentary indicates that Enliven's stock currently appears overvalued relative to its Fair Value assessment, with additional detail accessible through the platform's full financial health metrics.
Clinical update
Separately, Enliven disclosed positive initial results from its Phase 1b study of ELVN-001, a candidate for chronic myeloid leukemia (CML). Across the randomized 60 mg and 120 mg cohorts, the cumulative major molecular response (MMR) rate reached 69% by 24 weeks, and 53% of patients had achieved MMR by that time point. The randomized cohorts also showed a deep molecular response in 35% of patients. The company said it plans to move the program into Phase 3 later this year.
Board transition
Enliven announced a board appointment as well: Scott Garland will join the company's Board of Directors, replacing Andrew Phillips, Ph.D., who will step down effective January 7. The company characterized Garland as bringing more than 30 years of commercial leadership experience in the pharmaceutical industry.
What this collection of developments shows
The insider sale and option exercise, the upward move in the stock price, the InvestingPro valuation assessment, the Phase 1b clinical readout for ELVN-001, and the board-level change together depict a company progressing a clinical program while navigating market valuation dynamics and governance shifts. The clinical results and the move toward Phase 3 are directly relevant to Enliven's development trajectory in CML, and the insider activity offers a contemporaneous window into executive-level transactions tied to a pre-arranged trading plan.